tiprankstipranks
Trending News
More News >
Sanofi (GB:0O59)
LSE:0O59
UK Market
Advertisement

Sanofi (0O59) Share Forecast & Price Target

Compare
11 Followers
See the Price Targets and Ratings of:

0O59 Analyst Ratings

Strong Buy
14Ratings
Strong Buy
12 Buy
2 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Sanofi
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0O59 Stock 12 Month Forecast

Average Price Target

€105.39
▲(23.35% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €105.39 with a high forecast of €119.44 and a low forecast of €95.35. The average price target represents a 23.35% change from the last price of €85.44.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"€79","120":"€120","89.25":"€89.3","99.5":"€99.5","109.75":"€109.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119.44051890824927,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€119.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.3900031552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€105.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.3516747586864,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€95.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,89.25,99.5,109.75,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.6,90.04927068524994,92.49854137049988,94.94781205574984,97.39708274099978,99.84635342624972,102.29562411149966,104.7448947967496,107.19416548199955,109.64343616724949,112.09270685249945,114.54197753774939,116.99124822299933,{"y":119.44051890824927,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.6,88.96846178116922,90.33692356233846,91.70538534350769,93.07384712467692,94.44230890584615,95.81077068701538,97.17923246818461,98.54769424935385,99.91615603052308,101.28461781169231,102.65307959286154,104.02154137403078,{"y":105.3900031552,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.6,88.1962826737451,88.79256534749021,89.38884802123532,89.98513069498043,90.58141336872553,91.17769604247064,91.77397871621575,92.37026138996086,92.96654406370597,93.56282673745108,94.15910941119618,94.75539208494129,{"y":95.3516747586864,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.535,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.581,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.308,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.177,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.785,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.381,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.827,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.066,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.032,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€119.44Average Price Target€105.39Lowest Price Target€95.35
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Berenberg Bank Analyst forecast on GB:0O59
Berenberg Bank
Berenberg Bank
€110
Buy
28.75%
Upside
Reiterated
11/06/25
Berenberg Bank Remains a Buy on Sanofi (SNYNF)
Deutsche Bank  Analyst forecast on GB:0O59
Deutsche Bank
Deutsche Bank
€110
Buy
28.75%
Upside
Reiterated
10/30/25
Deutsche Bank Sticks to Its Buy Rating for Sanofi (SNYNF)
Goldman Sachs Analyst forecast on GB:0O59
Goldman Sachs
Goldman Sachs
€92€95
Hold
11.19%
Upside
Reiterated
10/28/25
Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (NASDAQ: ZBIO) and Sanofi (Other OTC: SNYNF)
Kepler Capital  Analyst forecast on GB:0O59
Kepler Capital
Kepler Capital
€95
Hold
11.19%
Upside
Reiterated
10/24/25
Kepler Capital Reaffirms Their Hold Rating on Sanofi (SNYNF)
UBS
€105
Buy
22.89%
Upside
Reiterated
10/24/25
UBS Sticks to Its Buy Rating for Sanofi (SNYNF)
DZ BANK AG Analyst forecast on GB:0O59
DZ BANK AG
DZ BANK AG
Buy
Reiterated
10/24/25
DZ BANK AG Sticks to Its Buy Rating for Sanofi (SNYNF)
Bernstein
€119
Buy
39.28%
Upside
Reiterated
10/24/25
Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)
Jefferies
€120€100
Buy
17.04%
Upside
Reiterated
10/24/25
Sanofi (SNYNF) Gets a Buy from Jefferies
Bank of America Securities Analyst forecast on GB:0O59
Bank of America Securities
Bank of America Securities
€115
Buy
34.60%
Upside
Reiterated
10/24/25
Sanofi: Buy Rating Affirmed on Strong Financials and Promising Growth Prospects
Leerink Partners Analyst forecast on GB:0O59
Leerink Partners
Leerink Partners
Buy
Reiterated
10/23/25
Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (NASDAQ: SOPH) and Sanofi (Other OTC: SNYNF)
J.P. Morgan Analyst forecast on GB:0O59
J.P. Morgan
J.P. Morgan
€105
Buy
22.89%
Upside
Reiterated
10/22/25
J.P. Morgan Sticks to Its Buy Rating for Sanofi (SNYNF)
Guggenheim
€104€101
Buy
18.21%
Upside
Reiterated
10/08/25
Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim
TR | OpenAI - 4o Analyst forecast on GB:0O59
TR | OpenAI - 4o
TR | OpenAI - 4o
€88€97
Buy
13.53%
Upside
Reiterated
10/02/25
AI Generated ArticleAI Generated Article
Morgan Stanley Analyst forecast on GB:0O59
Morgan Stanley
Morgan Stanley
€100
Buy
17.04%
Upside
Upgraded
09/08/25
Positive Report for Sanofi (SNYNF) from Morgan Stanley
Barclays Analyst forecast on GB:0O59
Barclays
Barclays
€115€105
Buy
22.89%
Upside
Reiterated
08/12/25
Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Berenberg Bank Analyst forecast on GB:0O59
Berenberg Bank
Berenberg Bank
€110
Buy
28.75%
Upside
Reiterated
11/06/25
Berenberg Bank Remains a Buy on Sanofi (SNYNF)
Deutsche Bank  Analyst forecast on GB:0O59
Deutsche Bank
Deutsche Bank
€110
Buy
28.75%
Upside
Reiterated
10/30/25
Deutsche Bank Sticks to Its Buy Rating for Sanofi (SNYNF)
Goldman Sachs Analyst forecast on GB:0O59
Goldman Sachs
Goldman Sachs
€92€95
Hold
11.19%
Upside
Reiterated
10/28/25
Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (NASDAQ: ZBIO) and Sanofi (Other OTC: SNYNF)
Kepler Capital  Analyst forecast on GB:0O59
Kepler Capital
Kepler Capital
€95
Hold
11.19%
Upside
Reiterated
10/24/25
Kepler Capital Reaffirms Their Hold Rating on Sanofi (SNYNF)
UBS
€105
Buy
22.89%
Upside
Reiterated
10/24/25
UBS Sticks to Its Buy Rating for Sanofi (SNYNF)
DZ BANK AG Analyst forecast on GB:0O59
DZ BANK AG
DZ BANK AG
Buy
Reiterated
10/24/25
DZ BANK AG Sticks to Its Buy Rating for Sanofi (SNYNF)
Bernstein
€119
Buy
39.28%
Upside
Reiterated
10/24/25
Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)
Jefferies
€120€100
Buy
17.04%
Upside
Reiterated
10/24/25
Sanofi (SNYNF) Gets a Buy from Jefferies
Bank of America Securities Analyst forecast on GB:0O59
Bank of America Securities
Bank of America Securities
€115
Buy
34.60%
Upside
Reiterated
10/24/25
Sanofi: Buy Rating Affirmed on Strong Financials and Promising Growth Prospects
Leerink Partners Analyst forecast on GB:0O59
Leerink Partners
Leerink Partners
Buy
Reiterated
10/23/25
Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (NASDAQ: SOPH) and Sanofi (Other OTC: SNYNF)
J.P. Morgan Analyst forecast on GB:0O59
J.P. Morgan
J.P. Morgan
€105
Buy
22.89%
Upside
Reiterated
10/22/25
J.P. Morgan Sticks to Its Buy Rating for Sanofi (SNYNF)
Guggenheim
€104€101
Buy
18.21%
Upside
Reiterated
10/08/25
Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim
TR | OpenAI - 4o Analyst forecast on GB:0O59
TR | OpenAI - 4o
TR | OpenAI - 4o
€88€97
Buy
13.53%
Upside
Reiterated
10/02/25
AI Generated ArticleAI Generated Article
Morgan Stanley Analyst forecast on GB:0O59
Morgan Stanley
Morgan Stanley
€100
Buy
17.04%
Upside
Upgraded
09/08/25
Positive Report for Sanofi (SNYNF) from Morgan Stanley
Barclays Analyst forecast on GB:0O59
Barclays
Barclays
€115€105
Buy
22.89%
Upside
Reiterated
08/12/25
Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

1 Month
xxx
Success Rate
30/46 ratings generated profit
65%
Average Return
+0.87%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +0.87% per trade.
3 Months
xxx
Success Rate
12/16 ratings generated profit
75%
Average Return
+1.90%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +1.90% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
26/34 ratings generated profit
76%
Average Return
+5.26%
reiterated a buy rating 17 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +5.26% per trade.
2 Years
xxx
Success Rate
19/25 ratings generated profit
76%
Average Return
+9.50%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.00% of your transactions generating a profit, with an average return of +9.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0O59 Analyst Recommendation Trends

Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
30
30
48
54
45
Hold
15
12
14
9
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
42
62
63
52
In the current month, 0O59 has received 45 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0O59 average Analyst price target in the past 3 months is 105.39.
Each month's total comprises the sum of three months' worth of ratings.

0O59 Financial Forecast

0O59 Earnings Forecast

Next quarter’s earnings estimate for 0O59 is €1.42 with a range of €1.31 to €1.75. The previous quarter’s EPS was €2.91. 0O59 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0O59 has Preformed in-line its overall industry.
Next quarter’s earnings estimate for 0O59 is €1.42 with a range of €1.31 to €1.75. The previous quarter’s EPS was €2.91. 0O59 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0O59 has Preformed in-line its overall industry.

0O59 Sales Forecast

Next quarter’s sales forecast for 0O59 is €11.66B with a range of €11.08B to €12.17B. The previous quarter’s sales results were ―. 0O59 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0O59 has Preformed in-line its overall industry.
Next quarter’s sales forecast for 0O59 is €11.66B with a range of €11.08B to €12.17B. The previous quarter’s sales results were ―. 0O59 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0O59 has Preformed in-line its overall industry.

0O59 Stock Forecast FAQ

What is GB:0O59’s average 12-month price target, according to analysts?
Based on analyst ratings, Sanofi’s 12-month average price target is 105.39.
    What is GB:0O59’s upside potential, based on the analysts’ average price target?
    Sanofi has 23.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sanofi a Buy, Sell or Hold?
          Sanofi has a consensus rating of Strong Buy, which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Sanofi’s share price target?
            The average share price target for Sanofi is 105.39. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €119.44 ,and the lowest forecast is €95.35. The average share price target represents 23.35% Increase from the current price of €85.44.
              What do analysts say about Sanofi?
              Sanofi’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Sanofi?
                To buy shares of GB:0O59, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis